Progression of Kidney Disease in Non-Diabetic Patients with Coronary Artery Disease: Predictive Role of Circulating Matrix Metalloproteinase-2, -3, and -9

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Hsu, Ta Wei ^a   Kuo, Ko Lin ^b   Hung, Szu Chun ^b   Huang, Po Hsun ^a,c   Chen, Jaw Wen ^c   Tarng, Der Cherng ^a,c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b Taipei Branch   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; STROMELYSIN;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE COURSE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROSPECTIVE STUDY;

AGED; CORONARY ARTERY DISEASE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY DISEASES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84880848565     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070132     Document Type: Article

References (38)

1. Catania JM, Chen G, Parrish AR, (2007) Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol 292: F905-911.
2. Visse R, Nagase H, (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92: 827-839.
3. Newby AC, (2005) Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 85: 1-31.
4. Dhillon OS, Khan SQ, Narayan HK, Nq KH, Mohammed N, et al. (2010) Matrix metalloproteinase-2 predicts mortality in patients with acute coronary syndrome. Clin Sci (Lond) 118: 249-257.
5. Wu TC, Leu HB, Lin WT, Lin CP, Lin SJ, et al. (2005) Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease. Eur J Clin Invest 35: 537-545.
6. Ye ZX, Leu HB, Wu TC, Lin SJ, Chen JW, (2008) Baseline serum matrix metalloproteinase-9 level predicts long-term prognosis after coronary revascularizations in stable coronary artery disease. Clin Biochem 41: 292-298.
7. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, et al. (2003) Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107: 1579-1585.
8. Lenz O, Elliot SJ, Stetler-Stevenson WG, (2000) Matrix metalloproteinases in renal development and disease. J Am Soc Nephrol 11: 574-581.
9. Lods N, Ferrari P, Frey FJ, Kappeler A, Berthier C, et al. (2003) Angiotensin-converting enzyme inhibition but not angiotensin II receptor blockade regulates matrix metalloproteinase activity in patients with glomerulonephritis. J Am Soc Nephrol 14: 2861-2872.
10. Nagano M, Fukami K, Yamagishi S, Ueda S, Kaida Y, et al. (2009) Circulating matrix metalloproteinase-2 is an independent correlate of proteinuria in patients with chronic kidney disease. Am J Nephrol 29: 109-115.
11. Chang HR, Yang SF, Li ML, Lin CC, Hsieh YS, et al. (2006) Relationships between circulating matrix metalloproteinase-2 and-9 and renal function in patients with chronic kidney disease. Clin Chim Acta 366: 243-248.
12. Ebihara I, Nakamura T, Shimada N, Koide H, (1998) Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am J Kidney Dis 32: 544-550.
13. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, et al (2009) CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612.
14. Davies DF, Shock NW, (1950) Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest 29: 496-507.
15. Glymour MM, Weuve J, Berkman LF, Kawachi I, Robins JM, (2005) When is baseline adjustment useful in analyses of change? An example of with education and cognitive change. Am J Epidemiol 162: 267-278.
16. Pencina MJ, D'Agostino RB, (2004) Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 23: 2109-2123.
17. Elsayed EF, Tighiouart H, Griffith J, Kurth T, Levey AS, et al. (2007) Cardiovascular disease and subsequent kidney disease. Arch Intern Med 167: 1130-1136.
18. Shlipak MG, Katz R, Kestenbaum B, Fried LF, Siscovick D, et al. (2009) Clinical and subclinical cardiovascular disease and kidney function decline in the elderly. Atherosclerosis 204: 298-303.
19. Uzu T, Kida Y, Shirahashi N, Harada T, Yamauchi A, et al. (2010) Cerebral microvascular disease predicts renal failure in type 2 diabetes. J Am Soc Nephrol 21: 520-526.
20. O'Hare AM, Rodriguez RA, Bacchetti P, (2005) Low ankle-brachial index associated with rise in creatinine level over time: results from the atherosclerosis risk in communities study. Arch Intern Med 165: 1481-1485.
21. Kiyosue A, Hirata Y, Ando J, Fujita H, Morita T, et al. (2010) Relationship between renal dysfunction and severity of coronary artery disease in Japanese patients. Circ J 74: 786-791.
22. National Kidney Foundation (2002) K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Am J Kidney Dis 39: S1-266.
23. Ronco P, Chatziantoniou C, (2008) Matrix metalloproteinases and matrix receptors in progression and reversal of kidney disease: therapeutic perspectives. Kidney Int 74: 873-878.
24. Zeisberg M, Neilson EG, (2010) Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 21: 1819-1834.
25. Bai Y, Wang L, Li Y, Liu S, Li J, et al. (2006) High ambient glucose levels modulates the production of MMP-9 and alpha5(IV) collagen by cultured podocytes. Cell Physiol Biochem 17: 57-68.
26. Fang Z, He F, Chen S, Sun X, Zhu Z, et al. (2009) Albumin modulates the production of matrix metalloproteinases-2 and-9 in podocytes. J Huazhong Univ Sci Technolog Med Sci 29: 710-714.
27. Li Y, Kang YS, Dai C, Kiss LP, Wen X, et al. (2008) Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am J Pathol 172: 299-308.
28. Kang YS, Li Y, Dai C, Kiss LP, Wu C, et al. (2010) Inhibition of integrin-linked kinase blocks podocyte epithelial-mesenchymal transition and ameliorates proteinuria. Kidney Int 78: 363-373.
29. Cheng S, Lovett DH, (2003) Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation. Am J Pathol 162: 1937-1949.
30. Cheng S, Pollock AS, Mahimkar R, Olson JL, Lovett DH, (2006) Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury. FASEB J 20: 1898-1900.
31. Toth M, Chvyrkova I, Bernardo MM, Hernandez-Barrantes S, Fridman R, (2003) Pro-MMP-9 activation by the MT1-MMP/MMP-2 axis and MMP-3: role of TIMP-2 and plasma membranes. Biochem Biophys Res Commun 308: 386-395.
32. Ogata Y, Enghild JJ, Nagase H, (1992) Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 267: 3581-3584.
33. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, et al. (1999) Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 274: 13066-13076.
34. Fridman R, Toth M, Pena D, Mobashery S, (1995) Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 55: 2548-2555.
35. Yan C, Boyd DD, (2007) Regulation of matrix metalloproteinase gene expression. J Cell Physiol 211: 19-26.
36. van Domburg RT, Hoeks SE, Welten GM, Chonchol M, Elhendy A, et al. (2008) Renal insufficnency and mortality in patients with known or suspected coronary artery disease. J Am Soc Nephrol 19: 158-163.
37. Son JW, Koh KK, Ahn JY, Jin DK, Park GS, et al. (2003) Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease. Int J Cardiol 88: 77-82.
38. Death AK, Nakhla S, McGrath KC, Martell S, Yue DK, et al. (2002) Nitroglycerin upregulates matrix metalloproteinase expression by human macrophages. J Am Coll Cardiol 39: 1943-1950.